GSK plc
GSK
View Detailed Chart
40.830USD
-0.630-1.52%
Close 09/12, 16:00（ET）Quotes delayed by 15 min
84.62BMarket Cap
19.13P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.52%
5 Days
+0.81%
1 Month
+4.08%
6 Months
+3.39%
Year to Date
+20.73%
1 Year
-5.07%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Hold
Current Rating
38.339
Target Price
-6.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Fairly Valued
The company’s latest PE is 18.68, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 378.08M shares, increasing 1.48% quarter-over-quarter.
Held by Van Duyn Dodge & E. Morris Cox
Star Investor Van Duyn Dodge & E. Morris Cox holds 78.76M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Ticker SymbolGSK
CompanyGSK plc
CEOMs. Deborah Waterhouse
Websitehttps://www.gsk.com/
Related Instruments
-0.17%
-0.24%
-0.84%
-1.90%
-2.80%
-2.72%
+1.14%
-2.24%
-2.81%
-3.94%
-1.30%
-0.77%
-2.81%
-1.23%
-0.61%
+0.03%
-1.60%
-0.60%
-1.44%
-0.15%
